目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T76524 | |||
Hepatitis C Virus S5A/5B是一种合成肽底物,模拟非结构蛋白(NS)的NS5A/5B连接,用于研究HCVNS3蛋白酶活性。 | |||
T76943 | |||
Cepeginterferon alfa-2b是一种聚乙二醇化干扰素, 其聚乙二醇基由分子量为20 kDa的PEG构成。该化合物广泛应用于丙型肝炎病毒(HCV)、真性红细胞增多症(PV)和原发性血小板增多症(ET)等疾病的研究中。 | |||
T76526 | |||
Ac-D-DGla-LI-Cha-C 是一种有效的HCV 蛋白酶抑制剂肽。Ac-D-DGla-LI-Cha-C 可用于癌症、自身免疫性疾病、纤维化疾病、炎症性疾病、神经退行性疾病、感染性疾病、肺部疾病、心脏和血管疾病以及代谢性疾病的研究。 | |||
T35533 | |||
6-Hydroxypyridin-3-ylboronic acid is a heterocyclic building block.1,2It has been used in the synthesis of non-nucleoside inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase nonstructural protein 5B (NS5B).16-Hydroxypyridin-3-ylboronic acid has also been used in the synthesis of mammalian target of rapamycin (mTOR) inhibitors.2 1.Hendricks, R.T., Spencer, S.R., Blake, J.F., et al.3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymeraseBioorg. Med. Chem. Lett.19(2)410-414(2009) 2.Verheijen, J.C., Richard, D.J., Curran, K., et al.Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and sselective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 6-aryl substituentJ. Med. Chem.52(24)8010-8024(2009) | |||
T73223 | HCV Protease | ||
NS5A-IN-3 (Compound 15) 为高效NS5A抑制剂,对HCV基因型1b显示出高效力,并对基因型3a (GT 3a) 活性提升以及展现出良好的代谢稳定性。NS5A-IN-3相较于daclatasvir,对基因型1b具有更高的耐药门槛。 | |||
T36860 | |||
C22 Sphingomyelin is a naturally occurring form of sphingomyelin . Plasma levels of C22 sphingomyelin positively correlate with hepatic steatosis severity in patients with chronic hepatitis C virus (HCV). C22 Sphingomyelin levels are decreased in T-47D mammary epithelial cells and increased in MDA-MB-231 breast cancer cells relative to C16 sphingomyelin . | |||
T38727 | |||
Azvudine hydrochloride (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI) that exhibits strong antiviral effects against HIV, HBV, and HCV. It demonstrates highly potent inhibition of HIV-1 (EC 50 ranging from 0.03 to 6.92 nM) and HIV-2 (EC 50 ranging from 0.018 to 0.025 nM). Additionally, Azvudine hydrochloride effectively inhibits NRTI-resistant viral strains. | |||
T25251 | |||
CID-7309015 is a human tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor, delayed death of the malarial parasite plasmid, the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1, ROR gamma transcriptiona | |||
T61871 | |||
DC-LC3in-D5 is a chemical compound that functions as an autophagy inhibitor by diminishing the process of LC3B lipidation. It forms a binding association with LC3B, disrupting the LC3B-LBP2 interaction with an IC50 of 200 nM. This compound, DC-LC3in-D5, exhibits potential for application in anti-HCV or combination cancer treatments by effectively inhibiting autophagy [1]. | |||
T36881 | |||
NHC-triphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) as a triphosphate form[1]. NHC-triphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA[1][2]. In an intracellular metabolism assay, HCV replicon cells are treated with 10 μM 3H-labeled NHC, and intracellular nucleotide levels are determined after 1, 2 and 8 hours incubations. NHC is rapidly convered into the mono-, di-, and triphosphate forms, and NHC-TP reaches up to 71.12 pM after 8 hours[1].NHC-triphosphate triammonium (NHC-TP) (5-40 μM) absence leads to full-length polymerization products, it can be a weak alternative substrate. In addition, incorporation of NHC-TP instead of CTP increases the molecular weight of the polymerization product by 16 (one extra oxygen) for each event and an obvious electrophoretic shift is observed in cell-free HCV NS5B polymerization reactions[1].Huh-7 cells are incubated with (10-50 μM; 4 h) NHC or a McGuigan phosphoramidate prodrug of NHC. Intracellular levels of the parental compounds and phosphorylated metabolites are measured using LC-MS/MS. Small amounts of NHC-monophosphate (MP) and NHC-diphosphate (DP) can be observed, while NHC-triphosphate triammonium remains the most abundant metabolite[2].NHC-triphosphate triammonium (NHC-TP) metabolite may directly target the viral polymerase and behave as a nonobligate chain terminator. It plays a prominent role in inhibiting early negative-strand RNA synthesis, either through chain termination or mutagenesis, which may in turn interfere with correct replicase complex formation. [1]. Stuyver LJ,et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.Antimicrob Agents Chemother. 2003 Jan;47(1):244-54. [2]. Maryam Ehteshami, et al. Characterization of β-d- N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01564 | Hepatitis C virus (HCV-1a) E2 Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus (HCV-1a) E2 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 32 kDa and the accession number is NP_751921.1.
|
|||||
TMPY-00296 | Hepatitis C virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 32.2 kDa and the accession number is BAA03581.1.
|
|||||
TMPY-04135 | Hepatitis C virus Envelope Glycoprotein E1/HCV-E1 (subtype 1b, strain HC-J4) Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus Envelope Glycoprotein E1/HCV-E1 (subtype 1b, strain HC-J4) Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.7 kDa and the accession number is AAC15725.1.
|
|||||
TMPY-05166 | Hepatitis C virus (HCV) (serotype 1b, isolate HC-J4) Envelope/E2 Protein (His) | HCV | HEK293 Cells | ||
Hepatitis C virus (HCV) (serotype 1b, isolate HC-J4) Envelope/E2 Protein (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 32.4 kDa and the accession number is AAC15723.1.
|
|||||
TMPY-00323 | Hepatitis C virus (HCV-1a) NS3 protease/helicase immunodominant region Protein (aa 1356-1459, GST) | HCV | E. coli | ||
HCV NS3 displays three enzymatic activities: serine protease, NTPase, and RNA helicase. HCV NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B. HCV NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. One of the HCV proteases, NS3-4A serine protease, is a non-covalent heterodimer consisting of a catalytic subunit (the N-terminal one-third of NS3 protein) and an activating cofactor (NS4A protein) and is responsible for cleavage at four sites of the HCV polyprotein.
|
|||||
TMPJ-01273 | ACY3 Protein, Human, Recombinant (His) | Human | E. coli | ||
Aspartoacylase 3, also known as ACY3, N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming), Acylase III, Aminoacylase-3, Aspartoacylase-2, Aspartoacylase-2, HCV core-binding protein 1 and ASPA2, is a member of the Aspartoacylase subfamily. ACY3 plays an important role in deacetylating mercapturic acids in kidney proximal tubules and acts on N-acetyl-aromatic amino acids.ACY3 is located in the cytoplasm of S2 and S3 proximal tubules and the apical domain of S1 proximal tubules. ACY3 protein is also expressed at low levels in stomach, testis, heart, brain, lung and liver, and may function as an HCV (Hepatitis C virus) core binding protein.
|
|||||
TMPY-02285 | Influenza A H1N1 (A/Puerto Rico/8/34/Mount Sinai) Non-structural/NS2 Protein | H1N1 | E. coli | ||
Non-structural protein 2 (NS2) plays a crucial role in the hepatitis C virus (HCV) assembly. NS2 was predicted to be composed of three transmembrane (TM) segments. Hepatitis C virus (HCV) nonstructural protein 2 (NS2) is a hydrophobic, transmembrane protein that is required not only for NS2-NS3 cleavage but also for infectious virus production.NS2 protein is essential for hepatitis C virus (HCV) replication. NS2 protein was expressed and purified. Aptamers against NS2 protein were raised and antiviral effects of the aptamers were examined. The non-structural protein NS2, also called nuclear export protein, of influenza A virus contains a leucine-rich nuclear export signal that could guide viral ribonucleoproteins to cross the nuclear pore complex (NPC) and complete directional nucleocytoplasmic trafficking.
|
|||||
TMPH-01548 | IFI6 Protein, Human, Recombinant (B2M & His) | Human | E. coli | ||
Plays a role in apoptosis, negatively regulating the intrinsinc apoptotic signaling pathway and TNFSF10-induced apoptosis. However, it has also been shown to have a pro-apoptotic activity. Has an antiviral activity towards hepatitis C virus/HCV by inhibiting the EGFR signaling pathway, which activation is required for entry of the virus into cells.
|
|||||
TMPH-00848 | OASL Protein, Human, Recombinant (His) | Human | E. coli | ||
Does not have 2'-5'-OAS activity, but can bind double-stranded RNA. Displays antiviral activity against encephalomyocarditis virus (EMCV) and hepatitis C virus (HCV) via an alternative antiviral pathway independent of RNase L. OASL Protein, Human, Recombinant (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 65.1 kDa and the accession number is Q15646.
|
|||||
TMPH-01104 | Claudin-9 Protein-VLP, Human, Recombinant (His) | Human | HEK293 Cells | ||
Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells. Claudin-9 Protein-VLP, Human, Recombinant (His) is expressed in HEK293 mammalian cells with C-10xHis tag. The predicted molecular weight is 24.2 kDa and the accession number is O95484.
|
|||||
TMPH-01248 | ADAR Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.
|
|||||
TMPH-00809 | Hepatitis C Genome polyprotein (His) | HCV | E. coli | ||
Hepatitis C Genome polyprotein (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 71.3 kDa and the accession number is S4UAW6.
|
|||||
TMPJ-01330 | CD299 Protein, Human, Recombinant (His & Flag) | Human | HEK293 Cells | ||
CD299 is also known as DC-SIGNR and CLEC4M, is a type II integral membrane protein. DC-SIGNR exists as a homotetramer, and the tandem repeat domain, also called neck domain, mediates oligermerization. Multiple human DC-SIGN/CD209 splice forms exist, generating both membrane-bound and soluble forms. DC-SIGNR is ragarded as a pathogen-recognition receptor involved in peripheral immune surveillance in liver, and probably mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. DC-SIGNR appears to selectively recognize and bind many viral surface glycoproteins containing high mannose N-linked oligosaccharides in a calcium-dependent manner, including HIV-1 gp12, HIV-2 gp12, SIV gp12, ebolavirus glycoproteins, HCV E2, and human SARS coronavirus protein S, as well as the cellular adhesion protein ICAM3. DC-SIGN/CD209 is expressed on dendritic cells (DC) and inflammatory macrophages and contributes to antigen presentation.
|
|||||
TMPY-02193 | GOLPH2/GOLM1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Golgi membrane protein 1, also known as Golgi membrane protein GP73, Golgi phosphoprotein 2, and GOLM1, is a protein that belongs to the GOLM1 / CASC4 family. GOLM1 is widely expressed. It is highly expressed in the colon, prostate, trachea, and stomach. It is expressed at a lower level in testis, muscle, lymphoid tissues, white blood cells, and spleen. It is predominantly expressed by cells of the epithelial lineage. GOLM1 is expressed at a low level in the normal liver. Expression significantly increases in virus (HBV, HCV) infected liver. Expression of GOLM1 does not increase in liver disease due to non-viral causes (alcohol-induced liver disease, autoimmune hepatitis). Increased expression in hepatocytes appears to be a general feature of advanced liver disease. In liver tissue from patients with adult giant-cell hepatitis (GCH), GOLM1 is strongly expressed in hepatocyte-derived syncytial giant cells. GOLM1 is constitutively expressed by biliary epithelial cells but not by hepatocytes.
|